Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.68 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9055150 | 0.88 | HPGD (0.89) | HPGDPOLBALDH1A1HDAC1SMN1; SMN2 | |
| SCHEMBL12506291 | 0.87 | CACNA1B (0.73) | HPGDPOLBCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL10198780 | 0.84 | CACNA1B (0.68) | CACNA1BAPBA1ALDH1A1HDAC1KMT2A | |
| SCHEMBL3690383 | 0.83 | POLB (0.79) | HPGDPOLBALDH1A1SMN1; SMN2NPC1 | |
| N-O-Tolylbenzamide SCHEMBL3223289 | 0.83 | HPGD (1.00) | HPGDPOLBALDH1A1HDAC1NPC1 | |
| SCHEMBL14299600 | 0.83 | CACNA1B (0.66) | CACNA1BAPBA1ALDH1A1HDAC1KMT2A | |
| Tacedinaline SCHEMBL29482198 | 0.83 | HDAC1 (0.74) | CACNA1BAPBA1HDAC1 | |
| Tacedinaline SCHEMBL144794 | 0.83 | HDAC1 (0.74) | CACNA1BAPBA1HDAC1 | |
| SCHEMBL2606722 | 0.82 | HDAC1 (0.59) | HPGDPOLBCACNA1BAPBA1HDAC1 | |
| SCHEMBL10357487 | 0.82 | CACNA1B (0.65) | HPGDPOLBCACNA1BAPBA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266822-B2 | Solid forms of tacedinaline | THE BROAD INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140275268-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8729130-B2 | Methods of using novel solid forms of tacedinaline | THE BROAD INSTITUTE, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130150450-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130039998-A1 | COMPOSITIONS OF MODULATORS OF THE WNT/BETA-CATENIN PATHWAY AND BENZAMIDE AND/OR HYDROXAMIC ACID DERIVATIVES TO TREAT BIPOLAR DISORDER | UNIVERSITY OF WASHINGTON (US) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039998-A1 | COMPOSITIONS OF MODULATORS OF THE WNT/BETA-CATENIN PATHWAY AND BENZAMIDE AND/OR HYDROXAMIC ACID DERIVATIVES TO TREAT BIPOLAR DISORDER | GSK3A, GSK3B, WNT3A | HPGD 1334/4885POLB 3465/4885CACNA1B 1205/4885 |
| US-20130150450-A1 | NOVEL SOLID FORMS OF TACEDINALINE | ACSS2, SLC10A1, ACAT2 | HPGD 3659/4885POLB 2229/4885CACNA1B 2629/4885 |
| US-20140275268-A1 | NOVEL SOLID FORMS OF TACEDINALINE | ACSS2, FAM162A, ACAT2 | HPGD 4017/4885POLB 1675/4885CACNA1B 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.